ImpediMed Limited (IPD) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Pamjot Bains, the CEO and Managing Director of Impedimet. Pamjot. Great. Thank you. Good morning and thank you for joining us to discuss the Q1 FY26 results. We're using our new Impedimet Investor Hub to host the webinar and I'm pleased to be here with McGregor Grant, our CFO. and Scott Long, our SVP of Sales. We'll be referencing the 4C quarterly activity report and presentation we launched this morning with the ASX. The presentation is a summary of the more detailed 4C. After our remarks, we'll be taking your questions. You can lodge your questions through the presentation, throughout the presentation using the Investor Hub Q&A function. A couple of opening remarks. I've just returned from two weeks traveling through the US, managed to get a cold, hence the voice is a bit weak. I've spent much of the time in Texas meeting with customers and potential customers in lymphedema, heart failure, and in body comp. It's always been really invigorating meeting with the clinicians who are using SOZO with their patients and also seeing the opportunity that is created through the lymphedema business to extend into other indications. The demand for SOZO and the value it generates for patients and clinicians is clearly very evident. I was especially encouraged with our heart failure meetings and the feedback we received for SOZO Pro and the level of information that the new device provides. And I think also what's happening with body comp in the United States is nothing short of astounding. We just don't have anything like it happening in Australia, although I say that yet. From med spas to longevity and hydration clinics, the entire space is exploding on the back of the GLP-1 drugs, with many of these clinics now prescribing GLP-1 drugs to provide weight loss management service...